News

Learning how to prescribe biologics, talking to mentors, reviewing journals, and getting involved in clinical trials are all ways to boost your expertise.

Silverberg discusses how certain irritants and living situations may cause flares in patients with atopic dermatitis.

The investigational oral JAK1 inhibitor showed promising results for vitiligo patients.

Researchers determined a statistically significant improvement to patient quality of life post-transplant.

Late-breaking positive phase 2a results were presented at AAD 2023.

AbbVie announced study results demonstrating efficacy in patients with a history of previous interleukin-17 inhibitor therapy.

Click here to answer this week's poll.

Although the ingredient is widely used in skincare, the American Contact Dermatitis Society (ACDS) wants clinicians to take special considerations when patch testing for lanolin contact allergy.

Researchers say women who experience hair loss may experience conditions like acne, breast cancer, and diabetes.

Research suggests that as metal allergies and implants grow in frequency, some patients may need to consult a dermatologist for treatment.

ICYMI, this week we had stories about session highlights from AAD 2023, FDA approvals of biosimilars and MCC treatments, the association between the Mediterranean diet and tumor response rates, and more.

The UK and Netherlands study assessed tumor response rates among 91 patients.

Researchers say the treatment is both safe and effective in moderate-to-severe cases.

Researchers say the impacts may be more harmful than those caused by industrial air pollutants.

More than 300 innovative sessions, an engaging exhibit hall, and heartfelt networking—there was a lot to pack into AAD 2023! Here are the highlights.

The study also found lasting benefits of the supplement for bone density up to age 4.

Study investigators said this system could have significant clinical implications.

The selective and reversible Janus kinase inhibitor is being studied in several immune-mediated inflammatory diseases.

Pregnant women with atopic dermatitis and psoriasis may require special treatment considerations.

In part 3 of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

Miller shares upcoming news from the SDPA and important legislative updates for dermatology physician assistants.

DermaSensor’s handheld device is awaiting FDA review.

Researchers were unable to determine a definite correlation.

Researchers sought to analyze alopecia areata data in populations historically underrepresented in research.

Phase 3 data of Oleogel-S10 was presented in a late-breaking session at AAD 2023 in New Orleans.

Incyte’s MCC indication is approved under accelerated approval based on tumor response rate and duration of response.

Prior use of biologics in patients with plaque psoriasis may not impact the efficacy of risankizumab treatment.

Timber Pharmaceuticals is on its way to developing the first FDA-approved treatment for congenital ichthyosis subtypes.

Results from the phase 3 DERMIS-1 and DERMIS-2 trials were presented at the 2023 American Academy of Dermatology Annual Meeting.